These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 1924448

  • 1. Urinary evaluation of tumor-associated antigens in urothelial bladder tumors.
    Piana P, Casetta G, Cavallini A, Piantino P, Tizzani A.
    Prog Clin Biol Res; 1991; 370():179-84. PubMed ID: 1924448
    [No Abstract] [Full Text] [Related]

  • 2. [Urine determination of CEA, CA50 and TPA as tumor markers in bladder neoplasms].
    Morote J, López-Pacios MA, Encabo G, de Torres JA.
    Med Clin (Barc); 1990 Jun 16; 95(3):119. PubMed ID: 2123505
    [No Abstract] [Full Text] [Related]

  • 3. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT, Casasola Chamorro J, Rodríguez Faba O, Martín Benito JL, Regadera Sejas FJ.
    Arch Esp Urol; 2002 Jun 16; 55(1):41-9. PubMed ID: 11957750
    [Abstract] [Full Text] [Related]

  • 4. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
    Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P, Bouchot O, Beurton D, Coulange C, Rambeaud JJ.
    J Urol; 2003 Mar 16; 169(3):921-4. PubMed ID: 12576813
    [Abstract] [Full Text] [Related]

  • 5. [Blood and urinary values of CEA and CA 19-9 in patients with bladder carcinoma].
    Cicigoi A, Rocca Rossetti S, Piantino P, Cerchier A.
    Minerva Med; 1986 Nov 10; 77(42-43):1983-7. PubMed ID: 3464851
    [Abstract] [Full Text] [Related]

  • 6. [Clinicopathological study of urinary bladder tumors. Clinical evaluation of immunohistochemistry in urine cytology].
    Nagata Y, Kinoshita H, Kawamura N, Sasadaira S.
    Hinyokika Kiyo; 1985 Nov 10; 31(11):1931-7. PubMed ID: 4091136
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
    Cai T, Mazzoli S, Meacci F, Tinacci G, Nesi G, Zini E, Bartoletti R.
    J Urol; 2007 Nov 10; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
    [Abstract] [Full Text] [Related]

  • 8. Urinary levels of tumour associated antigens (CA 19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities.
    Casetta G, Piana P, Cavallini A, Vottero M, Tizzani A.
    Br J Urol; 1993 Jul 10; 72(1):60-4. PubMed ID: 8149183
    [Abstract] [Full Text] [Related]

  • 9. Considerations on the use of urine markers for bladder cancer.
    van Rhijn BW.
    Eur Urol; 2008 May 10; 53(5):880-1. PubMed ID: 18222604
    [No Abstract] [Full Text] [Related]

  • 10. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS, Bagiella E, Sawczuk AT, Yun EJ.
    Cancer Detect Prev; 2000 May 10; 24(4):364-8. PubMed ID: 11059567
    [Abstract] [Full Text] [Related]

  • 11. Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma.
    Yao WJ, Chang CJ, Chan SH, Chow NH, Cheng HL, Tzai TS, Lin SN.
    Anticancer Res; 1995 May 10; 15(6B):2819-23. PubMed ID: 8669871
    [Abstract] [Full Text] [Related]

  • 12. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
    Moussa M, Omran Z, Nosseir M, Lotfy A, Swellam T.
    APMIS; 2009 Jan 10; 117(1):45-52. PubMed ID: 19161536
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I, Papadopoulos G, Iordanidou L, Stathouros G, Tzavara C, Gregorakis A, Lykourinas M.
    Urology; 2008 Nov 10; 72(5):1159-63. PubMed ID: 18514770
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D.
    Cancer; 2002 Jun 01; 94(11):2914-22. PubMed ID: 12115379
    [Abstract] [Full Text] [Related]

  • 15. Carcinoembryonic antigen and urothelial carcinoma.
    Hall RR, Laurence DJ, Neville AM, Wallace DM.
    Br J Urol; 1973 Feb 01; 45(1):88-92. PubMed ID: 4690154
    [No Abstract] [Full Text] [Related]

  • 16. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.
    Sánchez-Carbayo M, Herrero E, Megias J, Mira A, Espasa A, Chinchilla V, Soria F.
    J Urol; 1999 Apr 01; 161(4):1110-5. PubMed ID: 10081849
    [Abstract] [Full Text] [Related]

  • 17. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder.
    Allard P, Fradet Y, Têtu B, Bernard P.
    Clin Cancer Res; 1995 Oct 01; 1(10):1195-202. PubMed ID: 9815912
    [Abstract] [Full Text] [Related]

  • 18. [Serum and tissue quantification of tissue polypeptide antigen (TPA) in transitional cell carcinoma of the bladder].
    Moreno Sierra J, Maestro de las Casas ML, Ortega Heredia MD, Blanco Jimenez E, Hermida Gutiérrez J, Resel Estévez L.
    Arch Esp Urol; 1994 Dec 01; 47(10):979-84. PubMed ID: 7864679
    [Abstract] [Full Text] [Related]

  • 19. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
    Shi B, Laudon V, Yu S, Dong D, Zhu Y, Xu Z.
    Urol Int; 2008 Dec 01; 81(3):320-4. PubMed ID: 18931551
    [Abstract] [Full Text] [Related]

  • 20. The tumor markers CEA, TPA and CA 19-9 in gastric cancer.
    Putzki H, Reichert B, Jablonski M, Heymann H.
    Dtsch Z Verdau Stoffwechselkr; 1988 Dec 01; 48(3-4):145-8. PubMed ID: 3234297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.